Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H18F3N5OS |
| Molecular Weight | 421.439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN=C(S1)C2=NN=C(C=C2)N3CCC(CC3)OC4=CC=CC=C4C(F)(F)F
InChI
InChIKey=NVUJDKDVOZVALT-UHFFFAOYSA-N
InChI=1S/C19H18F3N5OS/c1-12-23-26-18(29-12)15-6-7-17(25-24-15)27-10-8-13(9-11-27)28-16-5-3-2-4-14(16)19(20,21)22/h2-7,13H,8-11H2,1H3
Thiadiazole-pyridazine derivative MF-438 has been identified as a potent stearoyl-CoA desaturase 1 (SCD1) inhibitor. Recently it has been shown that the upregulation of lung-cancer stem cell (CSC) markers can be reverted with a combination of MF-438 and cisplatin. The combination of MF-438 and cisplatin strongly synergizes the inhibition of 3D spheroid formation and induces CSC apoptosis.
Originator
Approval Year
Sample Use Guides
In Vitro Use Guide
Curator's Comment: Co-treatment with cisplatin and the SCD1 inhibitor MF-438 reverts upregulation of lung cancer stem cells (CSCs) markers, strongly synergizes in the inhibition of 3D spheroids formation and induces CSCs apoptosis. Mechanistically, SCD1 inhibition activates endoplasmic reticulum stress response and enhances autophagy.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
HI3FN320OX
Created by
admin on Mon Mar 31 18:18:50 GMT 2025 , Edited by admin on Mon Mar 31 18:18:50 GMT 2025
|
PRIMARY | |||
|
16042458
Created by
admin on Mon Mar 31 18:18:50 GMT 2025 , Edited by admin on Mon Mar 31 18:18:50 GMT 2025
|
PRIMARY | |||
|
921605-87-0
Created by
admin on Mon Mar 31 18:18:50 GMT 2025 , Edited by admin on Mon Mar 31 18:18:50 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
